What is the current stock price of Aptorum Group Limited (APM)?

As of the latest market data, Aptorum Group Limited (APM) is trading at $0.91. The stock has seen a gain of 9.43% today.

Does Aptorum Group Limited (APM) pay a dividend?

Based on current data, Aptorum Group Limited does not have a confirmed active dividend policy.

What is the market cap of Aptorum Group Limited?

The current market capitalization of Aptorum Group Limited (APM) is approximately unavailable.

APM

Aptorum Group Limited·Healthcare

0.91

9.428%(+0.08)

Market Closed

0.94

3.505%(+0.03)

After Hours

Last Updated: — ET

52W L: $0.6552W H: $4.47

APM NEWS

defenseworld.net

4d ago

Prelude Therapeutics (NASDAQ:PRLD) vs. Aptorum Group (NASDAQ:APM) Critical Review

Aptorum Group (NASDAQ: APM - Get Free Report) and Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk. Risk and Volatility Aptorum Group has a

defenseworld.net

Mar 27

Andean Precious Metals Q4 Earnings Call Highlights

Andean Precious Metals (TSE: APM) used its fourth-quarter and year-end earnings call to highlight what management described as a "step change" in 2025 results, driven by record financial performance, strong free cash flow, and a significantly strengthened balance sheet. Executives pointed to contributions from both the San Bartolomé silver operation and the Golden Queen gold operation,

seekingalpha.com

Mar 25

Andean Precious Metals Corp. (APM:CA) Q4 2025 Earnings Call Transcript

defenseworld.net

Mar 18

Aptorum Group Limited (NASDAQ:APM) Sees Significant Growth in Short Interest

Aptorum Group Limited (NASDAQ: APM - Get Free Report) was the target of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 11,553 shares, an increase of 14.8% from the February 12th total of 10,060 shares. Approximately 0.5% of the company's shares are sold short.

globenewswire.com

Mar 10

Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens” in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research.

Company Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2018-12-18

Beta

-0.01

Websitewww.aptorumgroup.com↗